Abstract Number: 1511 • 2013 ACR/ARHP Annual Meeting
What Impairs Balance In Ankylosing Spondylitis? Posture Or Disease Activity?
Background/Purpose: To compare ankylosing spondylitis (AS) patients and healthy individuals in terms of posture and balance and to identify the factors affecting balance among patients…Abstract Number: 1512 • 2013 ACR/ARHP Annual Meeting
Smoking and Its Relationship With Clinical, Radiological and Functional Status In Patients With Ankylosing Spondylitis
Background/Purpose: In recent years, smoking has been reported as an environmental risk factor that influence the course of certain diseases such as psoriasis, ulcerative colitis…Abstract Number: 1514 • 2013 ACR/ARHP Annual Meeting
Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register
Background/Purpose: Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…Abstract Number: 1515 • 2013 ACR/ARHP Annual Meeting
Influence Of Taking Structural Lesions Into Account In Addition To Inflammatory Lesions On MRI Of The Sacroiliac Joints On The Classification Of Patients With Possible Axial Spondyloarthritis
Background/Purpose: The ASAS definition of a positive MRI of the sacroiliac joints (MRI-SI+) for the classification of axial spondyloarthritis (axSpA) patients includes inflammatory lesions only1,2.…Abstract Number: 1516 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Etanercept In Early Non-Radiographic Axial Spondyloarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial At 24 Weeks
Background/Purpose: Limited data are available on the efficacy of anti-TNF agents in non-radiographic axial spondyloarthritis (nr-axSpA). The objective of this analysis is to compare the…Abstract Number: 1517 • 2013 ACR/ARHP Annual Meeting
Different Imaging Abnormalities Suggestive Of Spondyloarthritis Are Present In Early Axial Spondyloarthritis. Data From The DESIR Cohort
Background/Purpose: Patients can fulfil the ASAS (Assessment of SpondyloArthritiS) sets of criteria with either objective evidence of sacroiliac joint damage (X-Ray) or inflammation (MRI) (“imaging”…Abstract Number: 1518 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Spondylarthritis In Individuals Needing To Purchase An Orthopedic Mattress Because Of Chronic Back Pain
Background/Purpose: We hypothesize that the real prevalence of spondylarthritis (SpA) is much higher than reported in the literature. In this study, we aimed to investigate…Abstract Number: 1519 • 2013 ACR/ARHP Annual Meeting
Meeting The ACR 2010 Fibromyalgia Criteria Worsens Disease Activity and Quality Of Life In Patients With Axial Spondyloarthritis Treated With Infliximab
Background/Purpose: Managing axial spondyloarthritis (aSpA) may be difficult because sometimes patients are not good responder to anti-TNF. We made the hypothesis that in certain patients,…Abstract Number: 1520 • 2013 ACR/ARHP Annual Meeting
Reduction Of Disease Burden On Workplace and Household Productivity In Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, Over 48 Weeks Of Treatment With Certolizumab Pegol
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS, meeting modified New York criteria) and axSpA with no sacroiliitis on X-ray (non-radiographic axSpA, nr-axSpA). AS…Abstract Number: 1492 • 2013 ACR/ARHP Annual Meeting
Histone Deacetylase 1 But Not 2 Is Highly Expressed In The Lymphocyte Foci In The Labial Glands Of Patients With Sjogren’s Syndrome
Background/Purpose: Sjogren’s syndrome (SS) is an autoimmune disease with abnormally infiltrating lymphocytes in exocrine glands expressing Th1 cytokines and increased incidence of lymphoma. Histone deacetylases…Abstract Number: 1478 • 2013 ACR/ARHP Annual Meeting
The Prevalence Of Biological Monotherapy Among Rheumatoid Arthritis Patients In Denmark: Results From The Danish Nationwide Danbio Registry
Background/Purpose: It is estimated that between 10 and 30% of rheumatoid arthritis (RA) patients are methotrexate (MTX)-intolerant and discontinuation is common in clinical practice. For…Abstract Number: 1480 • 2013 ACR/ARHP Annual Meeting
Prevalance Of Rare Variants In Methotrexate Pathway Genes: Implications From The National Heart Lung Blood Institute (NHLBI) Exome Sequencing Project
Background/Purpose: Inter-individual variation to methotrexate (MTX) therapy in patients with rheumatoid arthritis (RA) is attributed at least in part to the presence of genetic variation…Abstract Number: 1479 • 2013 ACR/ARHP Annual Meeting
Relationship Between physicians’ Decision To Use Concomitant Glucocorticoid and Remission During Treatment With Tocilizumab In Patients With Background Of Limited Dose Of MTX
Background/Purpose: Now, predictive factors at baseline for the good outcome of treatment with biologics are very important not to waste time to treatment goal “remission”.…Abstract Number: 1481 • 2013 ACR/ARHP Annual Meeting
Negative Effect Of Glucocorticoids Persistence Therapy On Porosity In Rheumatoid Arthritis Patients Treated With TNFα Blockers
Background/Purpose: Rheumatoid arthritis is the most common joint inflammatory disease associated with an increased risk of bone fractures. The standard of therapeutic strategy is to…Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting
Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice
Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…